Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -49.19% is in line with its 5-year average of -47.35%, near the high end of its 5-year range (-163.94%–-20.81%).
As of the fiscal period ended Tuesday, June 30, 2026. 17.65% above its 12-month average of -59.74%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -49.19%.
RETURN ON EQUITY (ROE)
-49.19%
RETURN ON EQUITY (ROE) AVG TTM
-59.74%
RETURN ON EQUITY (ROE) AVG 3Y
-54.99%
RETURN ON EQUITY (ROE) AVG 5Y
-47.35%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+17.65%
CURRENT VS 3Y AVG
+10.54%
CURRENT VS 5Y AVG
-3.89%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.05%
median of 452 covered companies
CURRENT VS SECTOR MEDIAN
-29.27%
vs the sector median at left
Absci Corporation
Market Cap
$1.99B
Return on Equity (ROE)
-49.19%
TTM Avg
-59.74%
3Y Avg
-54.99%
5Y Avg
-47.35%
Market Cap
$1.99B
Return on Equity (ROE)
-179.99%
TTM Avg
-188.10%
3Y Avg
28.98%
5Y Avg
-2.67%
Market Cap
$2.02B
Return on Equity (ROE)
-13.09%
TTM Avg
-10.89%
3Y Avg
-18.29%
5Y Avg
-19.41%
Market Cap
$2.02B
Return on Equity (ROE)
51.09%
TTM Avg
25.46%
3Y Avg
0.90%
5Y Avg
-9.89%
Market Cap
$2.04B
Return on Equity (ROE)
-48.43%
TTM Avg
-97.59%
3Y Avg
-126.46%
5Y Avg
-100.04%
Market Cap
$2.05B
Return on Equity (ROE)
-8.14%
TTM Avg
-6.28%
3Y Avg
-6.47%
5Y Avg
-2.03%
Market Cap
$2.05B
Return on Equity (ROE)
N/A
TTM Avg
-101.38%
3Y Avg
-17.29%
5Y Avg
175.33%
Market Cap
$2.06B
Return on Equity (ROE)
16.36%
TTM Avg
13.19%
3Y Avg
3.41%
5Y Avg
-4.94%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Absci Corporation (ABSI) | $1.99B | -49.19% | -59.74% | -54.99% | -47.35% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.99B | -179.99% | -188.10% | 28.98% | -2.67% |
| AxoGen, Inc. (AXGN)vs › | $2.02B | -13.09% | -10.89% | -18.29% | -19.41% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 51.09% | 25.46% | 0.90% | -9.89% |
| Alvotech (ALVO)vs › | $2.04B | N/A | 23.18% | 49.13% | 48.50% |
| Immunome, Inc. (IMNM)vs › | $2.04B | -48.43% | -97.59% | -126.46% | -100.04% |
| Azenta, Inc. (AZTA)vs › | $2.05B | -8.14% | -6.28% | -6.47% | -2.03% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.05B | N/A | -101.38% | -17.29% | 175.33% |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.06B | 16.36% | 13.19% | 3.41% | -4.94% |
| Fortrea Holdings Inc. (FTRE)vs › | $2.09B | -16.25% | -99.56% | -48.75% | -32.00% |
ROE
-49.2%
ROA
-45.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -49.19% |
| 2026-03-31 | -68.87% |
| 2025-12-31 | -60.80% |
| 2025-09-30 | -54.49% |
| 2025-06-30 | -65.35% |
| 2025-03-31 | -54.06% |
| 2024-12-31 | -57.56% |
| 2024-09-30 | -48.51% |
| 2024-06-30 | -41.66% |
| 2024-03-31 | -45.47% |
| 2023-12-31 | -62.76% |
| 2023-09-30 | -54.22% |
| 2023-06-30 | -51.88% |
| 2023-03-31 | -38.89% |
| 2022-12-31 | -38.23% |
| 2022-09-30 | -37.75% |
| 2022-06-30 | -33.83% |
| 2022-03-31 | -35.09% |
| 2021-12-31 | -27.58% |
| 2021-09-30 | -20.81% |
| 2021-06-30 | -163.94% |
| 2021-03-31 | -36.04% |
| 2020-12-31 | -21.42% |
